 The major barrier to establishing a once daily medication regimen in maintenance kidney transplant recipients i.e. patients 12 months post transplantation was related to the requirement to prescribe calcineurin inhibitors twice daily. The development of Advagraf tacrolimus extended release capsules, which is approved for prevention of rejection in kidney transplant recipients, now provides an opportunity to convert patients to a once daily immunosuppressant medication regimen. 